PCSK9 inhibitors and dyslipidemia: The clinical evidence
Elevated plasma LDL cholesterol (LDL-C) levels are associated with cardiovascular diseases and statin therapy was proven to decrease LDL-C and reduce cardiovascular death. However, in patients at high cardiovascular risk, achievement of optimal LDL-C levels is challenging, and therefore additional s...
| Main Author: | |
|---|---|
| Format: | Journal Article |
| Published: |
2014
|
| Online Access: | http://hdl.handle.net/20.500.11937/55905 |